Lupin receives FDA approval for generic Potassium Chloride Oral Solution USP

It is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis

Pharma company Lupin announced that it has received approval for its Potassium Chloride Oral Solution USP, 20 mEq/15 mL (10 per cent) and 40 mEq/15 mL (20 per cent) from the United States Food and Drug Administration (FDA) to market a generic version of Genus Lifesciences, Inc.’s Potassium Chloride Oral Solution USP, 20 mEq/15 mL (10 per cent) and 40 mEq/15 mL (20 per cent).

It is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods and/or diuretic dose reduction are insufficient.

Potassium Chloride Oral Solution USP, 20 mEq/15 mL (10 per cent) and 40 mEq/15 mL (20 per cent) had annual sales of approximately USD 184.95 million in the US (IQVIA MAT June 2018).